Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Galactosylation variations in marketed therapeutic antibodies

1 May 2012

Abstract excerpt

There are currently ~25 recombinant full-length IgGs (rIgGs) in the market that have been approved by regulatory agencies as biotherapeutics to treat various human diseases. Most of these are based on IgG1k framework and are either chimeric, humanized or human antibodies manufactured using either Chinese hamster ovary (CHO) cells or mouse myeloma cells as the expression system. Because CHO and mouse myeloma cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Protein purification and stability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22531450
DOI: 10.4161/mabs.19868

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Galactosylation variations in marketed therapeutic antibodiesPMID 22531450Read ↗

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector ActivitiesSemantic proximity Read ↗

Glycosylation Shapes the Efficacy and Safety of Diverse Protein, Gene and Cell TherapiesSemantic proximity Read ↗

Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapiesSemantic proximity Read ↗

Antibody glycosylation in inflammation, disease and vaccinationSemantic proximity Read ↗

Generation and Comparative Characterization of Glycosylated and Aglycosylated Human IgG1 AntibodiesSemantic proximity Read ↗

Antibody therapeutics:Semantic proximity Read ↗

The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.Semantic proximity Read ↗

Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics.Semantic proximity Read ↗

Cell-based production of Fc-GlcNAc and Fc-alpha-2,6 sialyl glycan enriched antibody with improved effector functions through glycosylation pathway engineeringSemantic proximity Read ↗

Distribution of IgG galactosylation as a promising biomarker for cancer screening in multiple cancer typesSemantic proximity Read ↗

Effect of ADCC-enhancing mutations on N-glycan profiles of human IgG1 antibodies.Semantic proximity Read ↗

Unravelling Immunoglobulin G Fc N-Glycosylation: A Dynamic Marker Potentiating Predictive, Preventive and Personalised MedicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.